Home Mid-Atlantic Philadelphia, PA Century Therapeutics COMPANY
Clinical Phase 1
5 open jobs · last seen Oct 23, 2026 · 4 sources
Keywords: cell therapy iPSC oncology immunology metabolic autoimmune diseases type 1 diabetes cancer CRISPR protein engineering Systemic Lupus Erythematosus Lupus Nephritis Idiopathic Inflammatory Myopathies Diffuse Cutaneous Systemic Sclerosis R/R CD19-Positive B-Cell Malignancies Indolent Non-Hodgkin Lymphoma Aggressive Non-Hodgkin Lymphoma Hematological Malignancy Solid Tumor Malignancy CNTY-101 Show all 20 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Director, GMP Operations Branchburg, New Jersey Oct 19, 2026 Oct 20, 2026 Engineer, Process Development Branchburg, New Jersey Oct 13, 2026 Oct 14, 2026 Senior Director, Clinical Operations Branchburg, Philadelphia, Boston Oct 12, 2026 Oct 13, 2026 Director, Large Scale Process Development Branchburg, New Jersey Aug 24, 2026 Oct 11, 2026 Director, Translational Sciences Watertown, MA Jun 23, 2026 Oct 11, 2026
See all 5 jobs
At a glance HQ Philadelphia, PA source Region Mid-Atlantic Stage Clinical Phase 1 Latest trial Phase 1: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (Feb 6, 2025) source Timeline Jan 8, 2026 Raise Private placement: $135M (initial closing, as published), announced Jan 8, 2026. Source: SEC filing. source ↗ Feb 6, 2025 Trial start Phase 1: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases source ↗ Apr 29, 2024 Trial start —: A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product source ↗ Jan 24, 2023 Trial start Phase 1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies source ↗ Upcoming milestones 2028-08 (ESTIMATED) · Phase 1 · A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases · NCT06255028 2040-03 (ESTIMATED) · · A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product · NCT05768269 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $135.0M. Last 2 years.
Jan 8, 2026 Private placement: $135M (initial closing, as published), announced Jan 8, 2026. Source: SEC filing. source ↗ Clinical trials (lead sponsor) 3 Record Title Phase Status Start Primary completion NCT06255028 A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases Phase 1 Active, not recruiting Feb 6, 2025 2028-08 (estimated) NCT05336409 A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies Phase 1 Terminated Jan 24, 2023 Jul 1, 2025 (actual) NCT05768269 A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product Not listed Recruiting Apr 29, 2024 2040-03 (estimated)
Open jobs 5 Title Location (from posting, not HQ) Employer posted First seen Level Director, GMP Operations Branchburg, New Jersey Oct 19, 2026 Oct 20, 2026 Not stated Engineer, Process Development Branchburg, New Jersey Oct 13, 2026 Oct 14, 2026 Not stated Senior Director, Clinical Operations Branchburg, Philadelphia, Boston Oct 12, 2026 Oct 13, 2026 Not stated Director, Large Scale Process Development Branchburg, New Jersey Aug 24, 2026 Oct 11, 2026 Senior Description Director, Translational Sciences Watertown, MA Jun 23, 2026 Oct 11, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Century Therapeutics on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
